Studies Support Growing Use of the Accuray TomoTherapy System for Breast Cancer to Improve Tumor Control

Studies Support Growing Use of the Accuray TomoTherapy System for Breast Cancer to Improve Tumor Control
Studies presented at the 56th Annual American Society for Radiation Oncology (ASTRO) Meeting in San Francisco from September 14 to 17 reinforce broad-based healthcare professional support of the clinical and quality of life benefits Sunnyvale California-based Accuray Incorporated's CyberKnife and TomoTherapy radiation oncology systems deliver. A variety of indications including breast, prostate, lung, brain, and head and neck cancers were featured at the meeting, further positioning Accuray as a leader in precise, innovative tumor treatments. cyberknifeG4 ASTRO 2014 TomoTherapy clinical presentations focused on treatment of breast, brain, and head and neck cancers, and demonstrated the system's versatility, efficiency and effectiveness as a treatment for routine or more complex cases. Further information on this system is available here. Accuray cites a notable study [i] (see abstracts in Notes below) that highlighted results from an interim report of an ongoing IRB-approved phase 2 study on accelerated partial breast irradiation (APBI). With a median follow-up of 24 months, data support the use of TomoTherapy for APBI based on its ability to provide patients with decreased mean radiation dose to the heart (0.6 Gy) while providing meaningful local tumor control. A study [
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.